Patients with Renal Failure: When and How to Treat?
AASLD LiverLearning®. Roth D. Nov 14, 2016; 154725
Topic: Treatment
Label: HCV Symposium: Challenges in the DAA Era
Disclosure(s): Scientific Advisory Board for Merck Co, Consultant with Merck Co,
David Roth
David Roth

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting. A LiverLearning® Subscription ($150.00 US) grants access to LiverLearning® Premium content for one year after date of purchase. Click here to purchase your Premium Access Subscription now.


Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions